Rejuveron appoints anti-aging pioneer Aubrey de Grey to its Scientific Advisory Board
Schlieren, Zürich, Switzerland, 12 January 2021 .... Rejuveron Life Sciences AG, a Zürich-based biotechnology company developing technologies for healthy aging, today announced the appointment of biomedical gerontologist, Dr. Aubrey de Grey, to its Scientific Advisory Board (SAB).
De Grey joins Rejuveron’s current SAB members Prof. Lee Rubin (Harvard Stem Cell Institute) and Prof. Hideyuki Okano (Dean, Keio University School of Medicine).
De Grey is renowned for his work on using technological approaches to solve age-related health conditions. He is the Chief Science Officer of the non-profit SENS Research Foundation and editor-in-chief of the academic journal Rejuvenation Research.
Matthias Steger, CEO of Rejuveron said: “Aubrey De Grey’s expertise will bring an extra dimension to Rejuveron’s research into slowing down or reversing the aging process. His input will be invaluable for our incubator model, which aims to attract the best scientific brains in the field of aging,and support them in bringing their ideas to life.”
Aubrey de Grey said: “Rejuveron’s strategy fits perfectly with my own long-held ambitions of helping humans to live longer, healthier lives. Now that the biology of aging has transformed unequivocally from a basic science field to a biomedical one, and the private sector involvement is growing exponentially, I am delighted and honored to be able to contribute to the efforts of such a key player in the sector."
Caption - Dr. Aubrey de Grey
Copyright - Dr. Aubrey de Grey
About Aubrey de Grey
Dr. Aubrey de Grey is an English biomedical gerontologist. He is the Chief Science Officer of SENS Research Foundation and editor-in-chief of the academic journal Rejuvenation Research, He is also the author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007). De Grey is a fellow of the Gerontological Society of America, the American Aging Association, and the Institute for Ethics and Emerging Technologies.
Rejuveron Life Sciences AG is a fully integrated biotechnology platform company that invests in people and ideas to develop therapies and technologies to improve healthy aging and prolong lifespan.
Its team of experienced drug discovery and development experts provide start-up coaching and funding to entrepreneurial scientists. Rejuveron has state-of-the-art incubator laboratory facilities in Zürich’s Bio-Technopark in Schlieren.
For more information, please visit www.rejuveron.com
For media enquiries, please contact:
Free Range Communications
firstname.lastname@example.org +41 79 500 9824
Sue.email@example.com +44 7968 726585